MK-1088

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-1088, covering 2024-10-04 to 2024-10-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) [Phase 1, Phase 2]

See pricing